+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are conducting a phase 3 trial to evaluate the efficacy and safety of glepaglutide, given as 10 mg injections twice weekly, in adults with short bowel syndrome-intestinal failure SBS-IF. The study aims to confirm how well glepaglutide works in reducing the need for parenteral support PS and to collect additional long-term safety data. This trial is randomized, double-blind, and placebo-controlled, involving multiple centers. Participants receive either glepaglutide or placebo through subcutaneous injections twice weekly during the controlled phase. After this period, there is an open-label phase to assess long-term safety. No restorative surgery is planned during the trial, and participants must have stable PS needs and a small bowel length less than 200 cm. During the study, participants are monitored for changes in weekly PS volume and clinical response, with assessments up to 52 weeks. Safety is carefully tracked by recording any treatment-emergent adverse events. Participants undergo regular evaluations to measure treatment effects and overall health, ensuring comprehensive data collection throughout the study period.

Age: 18Years - 90YearsAll GendersPhase 3
33 locations
P

Actively Recruiting

Researchers are studying adults with Short Bowel Syndrome-associated Intestinal Failure SBS-IF to evaluate the safety, pharmacokinetics PK, and pharmacodynamics PD of the drug HM15912 sonefpeglutide. This is a Phase 2, randomized, double-blind, placebo-controlled, proof-of-concept study aimed at understanding how this subcutaneous medication affects people with this condition. Participants will go through several study phases including a screening period, a run-in period, a 6-month core treatment phase, a 7-month extension treatment phase, and a 1-month safety follow-up. They will receive either one of three doses of HM15912 0.5 mgkg, 1.0 mgkg, or 1.5 mgkg or a matching placebo, with treatments given by injection under the skin. Throughout the study, participants will be monitored for adverse events and assessed for drug safety, PK, and PD effects over 24 weeks. The study involves regular visits and evaluations to carefully track participants health and response to the treatment. The total duration includes the treatment and follow-up periods, ending with safety checks after the final treatment phase.

Age: 18Years +All GendersPhase 2
15 locations